Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,534.00    70.00 (2.84%)
Bid:
2,532.00
Ask:
2,534.00
Spread: 2.00 (0.079%)
Market Cap: £8.14b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

Today 07:00

RNS Number : 2843J
Bunzl PLC
23 June 2026
 

23 June 2026

 BUNZL PRE-CLOSE STATEMENT

2026 outlook upgraded; bolt-on acquisition completed in Australia

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2026.

Group revenue over the first half of 2026 is expected to grow by around 4% at constant exchange rates, with underlying revenue growth of around 3%. We expect growth to be supported by inflation across certain categories in the second quarter, with product-cost increases driven by geopolitical events, and we are also seeing encouraging volume growth. Volume growth is expected to be driven by North America, with good growth in our Distribution business. Our Distribution business continues to see operational progress as a result of actions taken, with encouraging volume growth across customers and supported by the additional benefit from new business wins that were achieved towards the end of last year. Over the first half, acquisitions, net of disposals, are expected to contribute growth of around 1% to the Group, and currency is expected to have a relatively neutral impact on revenue at actual exchange rates.

The Group expects good year-on-year growth in adjusted operating profit over the first half at constant exchange rates. Operating margin is expected to be up modestly year-on-year due to the net impact of inflation in the second quarter, much of which is expected to be temporary in nature, and the annualisation of Nisbets synergies.

While we remain mindful of continuing macroeconomic and geopolitical uncertainties, we are encouraged by our performance and upgrade our 2026 guidance. The Group now expects revenue growth at constant exchange rates to be driven by modest underlying revenue growth, supported by some inflation, alongside a small benefit from acquisitions. Our operating margin guidance is unchanged and we continue to expect it to be slightly down year-on-year.

In April, Bunzl completed the acquisition of Scientifix Group, an Australian distributor of critical products and services to the Life Sciences and Biotechnology sectors that will expand the category offering of our existing business. In the 12 months to June 2026, the business is expected to generate revenue of AUD 18 million (c.£9 million).

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

"Bunzl is expecting to deliver an improved performance in the first half, with continued underlying growth and robust profitability, demonstrating the resilience and agility of our business model. Furthermore, I am pleased that our North America Distribution business has achieved the good operational progress we had expected, with the business' responsiveness, agility and high service levels largely restored. We continue to expect 2026 to be a foundation for future profit growth.

I am also delighted to welcome Scientifix into the Group, a company that is an excellent strategic fit with our existing healthcare business in Australia, and further enhances our exposure to this attractive value-added sector. Our acquisition pipeline remains active and we continue to expect 2026 to be an improved year for acquisitions. We continue to see significant opportunities to further consolidate our fragmented global markets, and remain confident in our ability to generate long-term compounding growth and value creation for all of our stakeholders."

Conference call

There will be a live analyst and investor conference call and Q&A session from 8.00am (BST) today, hosted by Richard Howes (Chief Financial Officer). A replay will be available later in the day.

Dial-in number: + 44 20 3936 2999 / Access code: 534897

Enquiries:

Bunzl plc (Tel: +44 (0)20 7725 5000)

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations and Communications

Teneo (Tel: +44 (0)20 7353 4200)

Martin Robinson

Kate Somerville

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRGDLXGDDGLD
Date   Source Headline
3rd Jul 20234:45 pmRNSTotal Voting Rights
29th Jun 20233:26 pmRNSDirector/PDMR Shareholding
21st Jun 20234:54 pmRNSHolding(s) in Company
15th Jun 20237:00 amRNSTrading Statement
8th Jun 20238:00 amRNSAdditional Listing
5th Jun 202311:00 amRNSDirector/PDMR Shareholding
1st Jun 202311:16 amRNSTotal Voting Rights
30th May 20237:00 amRNSAcquisition
24th May 202312:16 pmRNSHolding(s) in Company
18th May 20238:00 amRNSAdditional Listing
3rd May 20234:15 pmRNSDirector/PDMR Shareholding
2nd May 20234:51 pmRNSDirector/PDMR Shareholding
2nd May 202310:37 amRNSDirector/PDMR Shareholding
2nd May 202310:30 amRNSTotal Voting Rights
2nd May 202310:27 amRNSBlock listing Interim Review
27th Apr 20238:00 amRNSAdditional Listing
26th Apr 20234:34 pmRNSResult of AGM
26th Apr 20237:00 amRNSTrading Statement
20th Apr 20238:00 amRNSAdditional Listing
19th Apr 20235:20 pmRNSHolding(s) in Company
13th Apr 20235:06 pmRNSDirector/PDMR Shareholding
12th Apr 20234:43 pmRNSDirector/PDMR Shareholding
11th Apr 20232:10 pmRNSDirector/PDMR Shareholding
11th Apr 20232:10 pmRNSDirector/PDMR Shareholding
11th Apr 202310:25 amRNSDirector/PDMR Shareholding
11th Apr 202310:17 amRNSDirector/PDMR Shareholding
5th Apr 20234:59 pmRNSDirector/PDMR Shareholding
3rd Apr 202312:30 pmRNSTotal Voting Rights
3rd Apr 202310:30 amRNSDirector/PDMR Shareholding
3rd Apr 20239:35 amRNSDirector/PDMR Shareholding
30th Mar 20238:00 amRNSAdditional Listing
28th Mar 202310:58 amRNSDirector/PDMR Shareholding
28th Mar 20239:21 amRNSDirector/PDMR Shareholding
23rd Mar 20238:00 amRNSAdditional Listing
16th Mar 202312:07 pmRNSAnnual Financial Report
16th Mar 20238:00 amRNSAdditional Listing
3rd Mar 20234:56 pmRNSDirector/PDMR Shareholding
2nd Mar 20233:20 pmRNSDirector/PDMR Shareholding
2nd Mar 202312:13 pmRNSDirector/PDMR Shareholding
2nd Mar 202312:09 pmRNSDirector/PDMR Shareholding
1st Mar 20234:31 pmRNSTotal Voting Rights
1st Mar 20234:02 pmRNSDirector/PDMR Shareholding
27th Feb 20232:00 pmRNSDividend Declaration
27th Feb 20237:00 amRNSFinal Results
27th Feb 20237:00 amRNSAcquisition
7th Feb 20237:00 amRNSDirectorate Change
6th Feb 20232:22 pmRNSDirector/PDMR Shareholding
2nd Feb 20237:00 amRNSCUSTOMER CONTRACT
1st Feb 202310:19 amRNSTotal Voting Rights
10th Jan 20233:44 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.